Cargando…
Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
BACKGROUND: Whether inflammation is independently associated with development of JAK2V617F mutation and myeloproliferative neoplasm is not clear. We tested the hypothesis that a loss-of-function polymorphism in IL6R (marked by rs4537545) reduces risk of JAK2V617F mutation and myeloproliferative neop...
Autores principales: | Pedersen, Kasper Mønsted, Çolak, Yunus, Ellervik, Christina, Hasselbalch, Hans Carl, Bojesen, Stig Egil, Nordestgaard, Børge Grønne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201035/ https://www.ncbi.nlm.nih.gov/pubmed/32382712 http://dx.doi.org/10.1016/j.eclinm.2020.100280 |
Ejemplares similares
-
Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020) -
Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020) -
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020) -
JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing
por: Mahe, Etienne, et al.
Publicado: (2019) -
Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)